Trial Profile

A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Phase 3 Study of Zipalertinib Plus Adjuvant Chemotherapy Versus Placebo Plus Adjuvant Chemotherapy in Stage IB-IIIA NSCLC Patients With Uncommon EGFR Mutations Following Complete Tumor Resection (REZILIENT4)

Status: Not yet recruiting

Phase of Trial: Phase III

Latest Information Update: 01 Sep 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carboplatin (Primary) ; Cisplatin (Primary) ; Pemetrexed (Primary) ; Zipalertinib (Primary)
Indications Non-small cell lung cancer
Focus Registrational; Therapeutic Use
Acronyms REZILIENT4
Sponsors Taiho Oncology

17 Aug 2025 Planned number of patients changed to 360.
16 Apr 2024 According to Cullinan Therapeutics media release, Cullinan Oncology has changed its name to Cullinan Therapeutics.
11 May 2023 According to an Cullinan Oncology media release, the company will continue the enrollment in this pivotal study at the 100mg BID dose only.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com